Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 674

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 674
---
 of the services are fully delivered to customers when performance obligations are met. This is recognized at an amount that reflects the consideration to which the Group expects to receive in exchange for transferring these services to customers (the “Transaction Price”). Heritas Diagnostics Segment Revenues from the Group’s Heritas Diagnostics segment are typically generated from genetic sequencing and diagnostics services covering the fields of oncology, prenatal care, rare diseases and clinical gut health, and provides other genetic sequencing services. The Group has entered into a commercial partnership with Cibic — Centro de Diagnóstico Medico de Alta Complejidad S.A. (“CIBIC”), a shareholder of OminigenicsAI Corp., for the purpose of providing these clinical genetic tests. Under this partnership agreement, CIBIC exclusively handles the commercialization of all Heritas Diagnostics clinical genetic tests in Argentina. (See Note 2.10 — Trade and other receivables, net) The Group identified a single performance obligation, namely, the delivery of the analysis results to CIBIC. The Group enables CIBIC to include these tests in its service portfolio, with CIBIC responsible to market these tests directly to patients and stakeholders in the healthcare industry, including physicians and healthcare institutions. CIBIC collects patient samples from its medical centers and delivers them to the Group’s laboratory for processing. Once the samples are received and processed, the Group generates reports with the results, which CIBIC then delivers to the patients and physicians. The Group establishes a price for each test, which CIBIC pays per test sold. CIBIC independently determines the retail price at which it sells these tests to end consumers. Revenue generated from selling the tests and other genetics sequencing services is recognized at a point in time when the reports with the results of the tests are sent to CIBIC. F-131

Notes to Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 2.Summary of significant accounting policies and basis of preparation (cont.) Rewell Segment The Rewell division provides at -homeDNA and microbiome test kits designed to support nutrition -basedhealth risk -managementand promote preventive health strategies through DNA and gut microbiome insights. The Group has identified two performance obligations, namely, the delivery of test results to the customer, and the provision of an upon -demandcomplementary coaching session to review test results and develop an actionable health plan. The transaction price includes the amount of fixed consideration the Group expects to receive. Revenue generated is recognized at a point in time when each